Switching to Dolutegravir + Lamivudine in a Highly Treatment-Experienced Patient Living with Human Immunodeficiency Virus Infection
Dolutegravir (DTG) + lamivudine (3TC) dual therapy regimen has entered the guidelines as a preferred first-line treatment regimen in antiretroviral treatment naïve individuals and as a switch regimen in cases with virologic suppression. Although clinical studies and real-life data suggest that virol...
Tallennettuna:
| Päätekijät: | , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Infectious Diseases and Clinical Microbiology Specialty Society of Turkey
2022-12-01
|
| Sarja: | Mediterranean Journal of Infection, Microbes and Antimicrobials |
| Aiheet: | |
| Linkit: | https://www.mjima.org/text.php?&id=356 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|